Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ELOX

Eloxx Pharmaceuticals (ELOX)

Eloxx Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ELOX
DateTimeSourceHeadlineSymbolCompany
16/04/202421:30GlobeNewswire Inc.Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program UpdatesNASDAQ:ELOXEloxx Pharmaceuticals Inc
02/04/202407:02Edgar (US Regulatory)Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405NASDAQ:ELOXEloxx Pharmaceuticals Inc
30/03/202407:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
22/03/202405:20Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
15/03/202407:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
14/03/202402:42GlobeNewswire Inc.Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseasesNASDAQ:ELOXEloxx Pharmaceuticals Inc
27/01/202408:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
27/01/202408:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
27/01/202408:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
27/01/202408:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
25/01/202413:44Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELOXEloxx Pharmaceuticals Inc
25/01/202409:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ELOXEloxx Pharmaceuticals Inc
10/01/202409:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
29/12/202308:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
14/11/202308:15GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:ELOXEloxx Pharmaceuticals Inc
17/10/202308:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
09/10/202323:00GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of ProteinuriaNASDAQ:ELOXEloxx Pharmaceuticals Inc
21/09/202306:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
21/09/202303:26Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ELOXEloxx Pharmaceuticals Inc
19/09/202322:00GlobeNewswire Inc.Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:ELOXEloxx Pharmaceuticals Inc
18/09/202322:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
18/09/202321:00GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeNASDAQ:ELOXEloxx Pharmaceuticals Inc
16/09/202307:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
08/09/202300:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
07/09/202323:00GlobeNewswire Inc.Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013NASDAQ:ELOXEloxx Pharmaceuticals Inc
30/08/202306:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
22/08/202306:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
15/08/202301:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
14/08/202322:30GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:ELOXEloxx Pharmaceuticals Inc
14/08/202322:00GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeNASDAQ:ELOXEloxx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ELOX